Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke

Cerebrovascular Diseases

Volumn 28, Issue 4, 2009, Pages 371-377

  Alvarez Sabín, José ^a   Penalba, Anna ^a   Quintana, Manolo ^a   Krupinski, Jerzy ^b,c   García Bonilla, Lidia ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Department of Neurology

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Aspirin; Cerebral ischemia; Chemokines; Interleukin 6; Neuroprotection; Stroke; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGENASE 3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SCATTER FACTOR; STROMELYSIN; STROMELYSIN 2; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIFLUSAL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; INFLAMMATION; MALE; NEUROMODULATION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SALICYLATES; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651224829     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000230711     Document Type: Article

References (19)

1. Fernandez de Arriba A, Cavalcanti F, Miralles A, Bayon Y, Alonso A, Merlos M, Garcia- Rafanell J, Forn J: Inhibition of cyclooxygenase- 2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol 1999; 55: 753-760
2. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, Melo T, TACIP Investigators: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, doubleblind, multicenter trial. Stroke 2003; 34: 840-848
3. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507
4. Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM: Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006; 17: 100-104
5. González-Correa JA, De La Cruz JP: Triflusal: An antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev 2006; 24: 11-24
6. Acarin L, González B, Castellano B: Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage. Stroke 2002; 33: 2499-2505
7. Whitehead SN, Bayona NA, Cheng G, Allen GV, Hachinski VC, Cechetto DF: Effects of triflusal and aspirin in a rat model of cerebral ischemia. Stroke 2007; 38: 381-387
8. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
10. González-Correa JA, Arrebola MM, Ureña IM, Guerrero A, Muñoz-Marín J, Ruiz-Villafranca D, Sánchez De La Cuesta F, De La Cruz JP: Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices. Brain Res 2004; 1011: 148-155
11. Acarin L, González B, Castellano B: Triflusal posttreatment inhibits glial nuclear factorkappaB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain. Stroke 2001; 32: 2394-2402
12. Vila N, Castillo J, Dávalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329
13. Wang Q, Tang XN, Yenari MA: The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68
14. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califa RM, Braunwald E: Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: Results from the A to Z trial. J Am Coll Cardiol 2007; 50: 2117-2124
15. Ay H, Ay I, Koroshetz WJ, Finklestein SP: Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 1999; 9: 131-135
16. Guo H, Huang L, Cheng M, Jin X, Zhao Y, Yi M: Serial measurement of serum basic fibroblast growth factor in patients with acute cerebral infarction. Neurosci Lett 2006; 393: 56-59
17. Valle M, Barbanoj MJ, Donner A, Izquierdo I, Herranz U, Klein N, Eichler HG, Müller M, Brunner M: Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. Eur J Clin Pharmacol 2005; 61: 103-111
18. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959
19. Buchan A: Advances in cerebral ischemia: Experimental approaches. Neurol Clin 1992; 10: 49-61